JACK ECKERD ACQUISITION OF 220 REVCO DRUG STORES
JACK ECKERD ACQUISITION OF 220 REVCO DRUG STORES will give the chain over 500 stores in both Florida and Texas. Eckerd, which now has 410 stores in Texas and 494 in Florida, will gain through the acquisition 138 Texas drugstores and 43 Florida drugstores. The agreement, announced June 5, will also expand the Clearwater, Florida-based chain's operations in Oklahoma, Mississippi and Louisiana, where Eckerd will add 18, 11 and 10 stores, respectively. Terms of the agreement were not disclosed. The 220 store purchase represents a 14% increase in Eckerd's store base, giving the privately held company almost 1,800 stores in its 13 states of operation and ranking it second behind Rite Aid in store count. Last year, Eckerd purchased 32 stores in three separate transactions: 15 stores in Atlanta via an agreement with Dunaway; five Texas stores from Hilleys; and 10 SupeRx stores in North Carolina. The firm also opened 50 new stores during the year. Eckerd, which also operates photolab and eyecare center businesses (roughly 300 labs/centers), did approximately $3.2 bil. in sales in 1989, with $1.2 bil. coming from pharmacy sales. * The Revco/Eckerd deal is part of Revco's Chapter 11 plan to divest 712 stores in 17 states. The agreement is subject to approval by the Akron federal bankruptcy court, where a hearing is expected to be scheduled for late June. Revco has another deal pending for sale of 221 of its outlets to Reliable Drug Stores ("The Pink Sheet" April 30, T&G-15). The reorganization plan calls for Revco to reduce its store base to approximately 1,100 stores in 10 continuous eastern states.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth